Online inquiry

IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7970MR)

This product GTTS-WQ7970MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL7R gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002185.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3575
UniProt ID P16871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7970MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10699MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ8480MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ15797MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ11764MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ5264MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ9428MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ13307MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ1931MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGS15C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW